Dr. Steven Shnyder,Associate Professor
Information about Dr. Steven Shnyder at the University of Bradford.
- School of Pharmacy & Medical Sciences
(Faculty of Life Sciences) - Email:
- s.d.shnyder@bradford.ac.uk
- Telephone:
- +44 1274 235898
Biography
Dr Steve Shnyder is a Senior Lecturer in Cancer Biology at the ICT. He has thirty-five years’ experience as a research scientist: 30 years post-doctoral, 18 months in a start-up pharma, with the past 24 years in a preclinical cancer pharmacology environment at Bradford. He has over 30 years’ experience of working with small mammals, mainly in the preclinical cancer pharmacology field. In his current position he is a Home Office Project and Personal Licence holder and is involved in the management and practical execution of Research and Knowledge Transfer in vivo and in vitro studies carried out at the ICT, working with both UK-based and international clients. His team has contributed to the screening packages of several novel anti-cancer compounds which have subsequently progressed to clinical trials and beyond, using both cell-based and in vivo technologies. He is an author on 80+ journal articles and numerous conference publications as well as four book chapters on in vivo methodology. In addition he has significant experience in the areas of histopathology, biochemistry and cell biology. He line manages a Research Associate whose focus is in vivo studies, and a Research Technician whose focus is in vitro screening. He is a strong proponent of 3Rs philosophy, always striving to apply the 3Rs to all the work he does, and he has been a co-investigator on 2 project grants and a studentship specifically aimed at improving methodology in preclinical cancer pharmacology from a 3Rs standpoint. Aside from this, his main research interests are focused around identifying mechanisms of drug resistance in colorectal cancer.
Research
Characterisation of the reticuloplasmins as anticancer drug targets. Pharmacology of vascular disrupting agents. Development of 3Rs methodologies. Exploitation of the fluorescent properties of anti-cancer therapeutics for utilisation in assessment of pharmacodynamic and pharmacokinetic end-points. Evaluation of the drugability of the tumour cell glycocalyx. Research Team Patricia Cooper, Experimental Officer Gary Lawson, Research Technician Marcella Sini, YCR Programme Grant Postdoctoral Researcher (with L Patterson, P Loadman, R Falconer & K Pors)
Professional activities
Information about education, employment and areas of particular interest for Dr. Steven Shnyder is as follows:
- British Society of Cell Biology (BSCB)
- British Association of Cancer Research (BACR)
Education
- Bradford - BSc
- Bradford - MPhil
- London - PhD
Publications
There are 85 publications involving or that are attributed to Dr. Steven Shnyder. They are listed as:
- book chapter (1)
- conference publication (2)
- peer reviewed journal (78)
- reviews (4)
Book Chapter
| Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncology Activity | 2015 | Drug Discovery and Evaluation: Pharmacological Assay, Fourth Edition | Drug Discovery and Evaluation: Pharmacological Assay, Fourth Edition | 4157 - 4200 | Gill J.;Shnyder S. | 9783319053929 | Springer | 10.1007/978-3-319-05392-9_113 |
Conference Publication
| Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017 | A Non-invasive 2D Digital Imaging Method for Detection of Surface Lesions Using Machine Learning | A Non-invasive 2D Digital Imaging Method for Detection of Surface Lesions Using Machine Learning | Hussain, Nosheen; Cooper, Patricia A.; Shnyder, Steven D.; Ugail, Hassan; Bukar, Ali M.; Connah, David | ||||||||
| A non-invasive 2D digital imaging method for detection of surface lesions using machine learning | 2017 | Proceedings - 2017 International Conference on Cyberworlds, CW 2017 - in cooperation with: Eurographics Association International Federation for Information Processing ACM SIGGRAPH | Proceedings - 2017 International Conference on Cyberworlds, CW 2017 - in cooperation with: Eurographics Association International Federation for Information Processing ACM SIGGRAPH | 2017-January | 166 - 169 | Hussain N.;Cooper P.;Shnyder S.;Ugail H.;Bukar A.;Connah D. | 9781538620892 | 10.1109/CW.2017.39 |
Peer Reviewed Journal
| Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A Proteomic Investigation to Discover Candidate Proteins Involved in Novel Mechanisms of 5-Fluorouracil Resistance in Colorectal Cancer | 2024 | Cells | 13 | Mario Ortega Duran, Sadr ul Shaheed , Christopher W. Sutton and Steven D. Shnyder | MDPI | https://doi.org/ 10.3390/cells13040342 | |||||
| Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds | 2021 | BIOORGANIC & MEDICINAL CHEMISTRY | 40 | Natalia Ortuzar, Kersti Karu, Daniela Presa, Goreti R. Morais, Helen M. Sheldrake, Steve D. Shnyder, Francis M. Barnieh, Paul M. Loadman, Laurence H. Patterson, Klaus Pors, Mark Searcey | 10.1016/j.bmc.2021.116167 | ||||||
| Synthesis and Biological Evaluation of Cyclobutane-Based β3 Integrin Antagonists: A Novel Approach to Targeting Integrins for Cancer Therapy | 2023 | Cancers | 15 | Mark Sutherland, Andrew Gordon, Fatemah OFO Al-Shammari, Adam Throup, Amy Cilia La Corte, Helen Philippou, Steven D Shnyder, Laurence H Patterson, Helen M Sheldrake | https://doi.org/10.3390/cancers15164023 | ||||||
| Semi-Synthetic Analogues of Cryptolepine as a Potential Source of Sustainable Drugs for the Treatment of Malaria, Human African Trypanosomiasis and Cancer | 2022 | Frontiers in Pharmacology | 13 | Abacha, YZ; Donkor Forkuo, A; Gbedema, SY; Mittal, N; Ottilie, S; Rocamora, F; Winzeler, EA; van Schalkwyk, DA; Kelly, JM; Taylor, MC; Reader, J; Birkholtz, L-M; Lisgarten, DR; Cockcroft, JK; Lisgarten, JN; Palmer, RA; Talbert, RC; Shnyder, SD, Wright, CW | doi: 10.3389/fphar.2022.875647 | ||||||
| Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer. | 2021 | Scientific Reports | 11 | Presa D;Khurram SA;Zubir AZA;Smarakan S;Cooper PA;Morais GR;Sadiq M;Sutherland M;Loadman PM;McCaul J;Shnyder SD;Patterson LH;Pors K; | 2045-2322 | 10.1038/s41598-021-98217-z | |||||
| The role of MT1-MMP in the progression and metastasis of osteosarcoma | 2022 | Journal of Cancer Metastasis and Treatment | 9 | Spencer, H.L.M.; Shnyder, S.D.; Loadman, P.M.; Falconer, R.A. | DOI:10.20517/2394-4722.2021.174 | ||||||
| Application of Small Molecule FPR1 Antagonists in the Treatment of Cancers | 2020 | Scientific Reports | na | Djevdet S. Ahmet, Haneen A. Basheer, Anwar Salem, Di Lu, Amin Aghamohammadi, Patrick Weyerhäuser, Andrea Bordiga, Juman Almeniawi, Sabah Rashid, Patricia A. Cooper, Steven D. Shnyder, Victoria Vinader, and Kamyar Afarinkia | Nature | https://doi.org/10.1038/s41598-020-74350-z | |||||
| An assay for quantitative analysis of polysialic acid expression in cancer cells | 2021 | Carbohydrate Polymers | 259 | Guo, X.; Elkashef, S.M.; Patel, A.; Ribeiro Morais, G.; Shnyder S.D.; Loadman, P.M.; Patterson, L.H.; Falconer, R.A. | 10.1016/j.carbpol.2021.117741 | ||||||
| Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds. | 2021 | Bioorganic and Medicinal Chemistry | 40 | Ortuzar N;Karu K;Presa D;Morais GR;Sheldrake HM;Shnyder SD;Barnieh FM;Loadman PM;Patterson LH;Pors K;Searcey M; | 1464-3391 | 10.1016/j.bmc.2021.116167 | |||||
| Preclinical Anticancer Activity of an Electron-Deficient Organoruthenium(II) Complex | 2020 | ChemMedChem | Soldevila-Barreda J.J.;Azmanova M.;Pitto-Barry A.;Cooper P.A.;Shnyder S.D.;Barry N.P.E. | 1860-7179 | 10.1002/cmdc.202000096 | ||||||
| An efficient assay for identification and quantitative evaluation of potential polysialyltransferase inhibitors. | 2020 | ANALYST (PRINT) | 145 | 4512 - 4521 | Guo X; Malcolm J.R.; Ali M.M.; Ribeiro Morais G; Shnyder S.D.; Loadman P.M.; Patterson L.H.; Falconer R.A. | 1364-5528 | 10.1039/d0an00721h | ||||
| Hypoxia modulates CCR7 expression in head and neck cancers | 2018 | Basheer, Haneen A.; Pakanavicius, E.; Cooper, Patricia A.; Shnyder, Steven D.; Martin, L.; Hunter, K.D.; Vinader, Victoria; Afarinkia, Kamyar | |||||||||
| Tubulin-binding dibenz[c,e]oxepines: Part 2.1Structural variation and biological evaluation as tumour vasculature disrupting agents | 2017 | Bioorganic and Medicinal Chemistry | 25 | 1630 - 1642 | Rossington S.;Hadfield J.;Shnyder S.;Wallace T.;Williams K. | 0968-0896 | 10.1016/j.bmc.2017.01.027 | ||||
| Agarose Spot as a Comparative Method for in situ Analysis of Simultaneous Chemotactic Responses to Multiple Chemokines | 2017 | Ahmed, Mohaned S.A.; Basheer, Haneen A.; Ayuso, J.M.; Ahmet, Djevdet; Mazzini, Marco; Patel, Roshan; Shnyder, Steven D.; Vinader, Victoria; Afarinkia, Kamyar | |||||||||
| Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands | 2017 | Cancer Letters | 397 | Allison, Simon J.; Sadiq, Maria; Baronou, Efstathia; Cooper, Patricia A.; Dunnill, C.; Georgopoulos, N.T.; Latif, A.; Shepherd, S.L.; Shnyder, Steven D.; Stratford, I.J.; Wheelhouse, Richard T.; Willans, C.; Phillips, Roger M. | |||||||
| Tubulin-binding dibenz[c,e]oxepines. Part 2. 1 Structural variation and biological evaluation as tumour vasculature disrupting agents | 2017 | Rossington, S.B.; Hadfield, J.A.; Shnyder, Steven D.; Wallace, T.W.; Williams, K.J. | |||||||||
| RGD-Binding Integrins in Head and Neck Cancers | 2017 | Ahmedah, H.T.; Patterson, Laurence H.; Shnyder, Steven D.; Sheldrake, Helen M. | |||||||||
| The use of thermographic imaging to evaluate therapeutic response in human tumour xenograft models | 2016 | Scientific Reports | 6 | 31136 | Hussain, Nosheen; Connah, David; Ugail, Hassan; Cooper, Patricia A.; Falconer, Robert A.; Patterson, Laurence H.; Shnyder, Steven D. | 10.1038/srep31136 | |||||
| The Effect of Polysialic Acid Expression on Glioma Cell Nano-mechanics | 2016 | BioNanoScience | 6 | 81 - 84 | Grant, Colin A.; Twigg, Peter C.; Saeed, Rida F.; Lawson, G.; Falconer, Robert A.; Shnyder, Steven D. | 10.1007/s12668-016-0192-2 | |||||
| PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma | 2016 | Ross, R.L.; McPherson, H.R.; Kettlewell, L.; Shnyder, Steven D.; Hurst, C.D.; Alder, O.; Knowles, M.A. | |||||||||
| Probing cytochrome P450-mediated activation with a truncated azinomycin analogue | 2015 | MedChemComm | 6 | 187 - 191 | Vinader, Victoria; Sadiq, Maria; Sutherland, Mark H.; Huang, M.Y.; Loadman, Paul M.; Elsalem, Lina M.I.; Shnyder, Steven D.; Cui, H.J.; Afarinkia, Kamyar; Searcey, M.; Patterson, Laurence H.; Pors, Klaus | dx.doi.org/10.1039/c4md00411f | |||||
| Thin-layer chromatography/matrix-assisted laser desorption/ionisation mass spectrometry and matrix-assisted laser desorption/ionisation mass spectrometry imaging for the analysis of phospholipids in LS174T colorectal adenocarcinoma xenografts treated with the vascular disrupting agent DMXAA | 2015 | Rapid Communications In Mass Spectrometry | 29 | 1288 - 1296 | Batubara, A.; Carolan, V.A.; Loadman, Paul M.; Sutton, Chris W.; Shnyder, Steven D.; Clench, M.R. | doi.org/10.1002/rcm.7223 | |||||
| Study of the chemotactic response of multicellular spheroids in a microfluidic device | 2015 | Ayuso, J.M.; Basheer, Haneen A.; Monge, R.; Sánchez-Álvarez, P.; Doblare, M.; Shnyder, Steven D.; Vinader, Victoria; Afarinkia, Kamyar; Fernandez, L.J.; Ochoa, I. | |||||||||
| Potent organometallic osmium compounds induce mitochondria-mediated apoptosis and S-phase cell cycle arrest in A549 non-small cell lung cancer cells | 2014 | van Rijt, S.H.; Romero-Canelón, I.; Fu, Y.; Shnyder, Steven D.; Sadler, P.J. | |||||||||
| Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity Against Solid Tumors and Reduced Potential For Cardiovascular Toxicity | 2014 | Molecular Cancer Therapeutics | 11 | 1294 - 1300 | Gill, Jason H.; Loadman, Paul M.; Shnyder, Steven D.; Cooper, Patricia A.; Atkinson, Jennifer M.; Ribeiro Morais, Goreti; Patterson, Laurence H.; Falconer, Robert A. | 10.1021/mp400760b | |||||
| Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins | 2013 | Travica, S.; Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Johansson, I.; Alandas, Mohammed N.; Sheldrake, Helen M.; Mkrtchian, S.; Patterson, Laurence H.; Ingelman-Sundberg, M. | |||||||||
| Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity | 2013 | Sheldrake, Helen M.; Travica, S.; Johansson, I.; Loadman, Paul M.; Sutherland, Mark H.; Elsalem, Lina M.I.; Illingworth, Nicola A.; Cresswell, Alexander J.; Reuillon, Tristan; Shnyder, Steven D.; Mkrtchian, S.; Searcey, M.; Ingelman-Sundberg, M.; Patterson, Laurence H.; Pors, Klaus | |||||||||
| NCAM polysialylation during adherence transitions: Live cell monitoring using an antibody-mimetic EGFP-endosialidase and the viability dye DRAQ7 | 2013 | Cytometry Part A | 83 | 659 - 671 | Smith P.;Furon E.;Wiltshire M.;Chappell S.;Patterson L.;Shnyder S.;Falconer R.;Errington R. | 1552-4922 | 10.1002/cyto.a.22306 | ||||
| Targeting of Hypoxia in AQ4N-treated Tumour Xenografts by MALDI-Ion Mobility Separation-Mass Spectrometry Imaging | 2013 | Djidja, M-C.; Francese, S.; Claude, E.; Loadman, Paul M.; Sutton, Chris W.; Shnyder, Steven D.; Cooper, Patricia A.; Patterson, Laurence H.; Carolan, V.A.; Clench, M.R. | |||||||||
| Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer | 2013 | Herrera-Abreu, M.T.; Pearson, A.; Campbell, J.; Shnyder, Steven D.; Knowles, M.A.; Ashworth, A.; Turner, N.C. | |||||||||
| Pharmacological Inhibition of polysialyltransferase ST8SiaII Modulates Tumour Cell Migration | 2013 | PLoS ONE | 8 | e73366 | Al-Saraireh, Yousef M.J.; Sutherland, Mark H.; Springett, Bradley R.; Freiberger, F.; Ribeiro Morais, Goreti; Loadman, Paul M.; Errington, R.J.; Smith, P.J.; Fukuda, M.; Gerardy-Schahn, R.; Patterson, Laurence H.; Shnyder, Steven D.; Falconer, Robert A. | 10.1371/journal.pone.0073366 | |||||
| Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder | 2013 | Sutherland, Mark H.; Gill, Jason H.; Loadman, Paul M.; Laye, Jonathan P.; Sheldrake, Helen M.; Illingworth, Nicola A.; Alandas, Mohammed N.; Cooper, Patricia A.; Searcey, M.; Pors, Klaus; Shnyder, Steven D.; Patterson, Laurence H. | |||||||||
| Synthesis and biological evaluation of colchicine C-ring analogues tethered with aliphatic linkers suitable for prodrug derivatisation | 2012 | Bioorganic and Medicinal Chemistry Letters | 22 | 7693 - 7696 | Fournier-Dit-Chabert J.;Vinader V.;Santos A.;Redondo-Horcajo M.;Dreneau A.;Basak R.;Cosentino L.;Marston G.;Abdel-Rahman H.;Loadman P.;Shnyder S.;Díaz J.;Barasoain I.;Falconer R.;Pors K. | 0960-894X | 10.1016/j.bmcl.2012.09.104 | ||||
| Synthesis and biological evaluation of colchicine B-ring analogues tethered with halogenated benzyl moieties | 2012 | Journal of Medicinal Chemistry | 55 | 11062 - 11066 | Cosentino L.;Redondo-Horcajo M.;Zhao Y.;Santos A.;Chowdury K.;Vinader V.;Abdallah Q.;Abdel-Rahman H.;Fournier-Dit-Chabert J.;Shnyder S.;Loadman P.;Fang W.;Díaz J.;Barasoain I.;Burns P.;Pors K. | 0022-2623 | 10.1021/jm301151t | ||||
| Polysialyltransferase: A new target in metastatic cancer | 2012 | Current Cancer Drug Targets | 12 | 925 - 939 | Falconer R.;Errington R.;Shnyder S.;Smith P.;Patterson L. | 1568-0096 | 10.2174/156800912803251225 | ||||
| Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo | 2011 | Cancer Gene Therapy | 18 | 773 - 784 | Harvey T.;Hennig I.;Shnyder S.;Cooper P.;Ingram N.;Hall G.;Selby P.;Chester J. | 0929-1903 | 10.1038/cgt.2011.43 | ||||
| An agarose spot chemotaxis assay for chemokine receptor antagonists | 2011 | Journal of Pharmacological and Toxicological Methods | 64 | 213 - 216 | Vinader V.;Al-Saraireh Y.;Wiggins H.;Rappoport J.;Shnyder S.;Patterson L.;Afarinkia K. | 1056-8719 | 10.1016/j.vascn.2011.01.004 | ||||
| The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo | 2011 | Burns, C.J.; Fantino, E.; Powell, A.K.; Shnyder, Steven D.; Cooper, Patricia A.; Nelson, S.; Christophi, C.; Malcontenti-Wilson, C.; Dubljevic, V.; Harte, M.F.; Joffe, M.; Phillips, I.D.; Segal, D.; Wilks, A.F.; Smith, G.D. | |||||||||
| Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo | 2011 | Lamont, F.R.; Tomlinson, D.C.; Cooper, Patricia A.; Shnyder, Steven D.; Chester, J.D.; Knowles, M.A. | |||||||||
| Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity | 2011 | Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Sutherland, Mark H.; Sheldrake, Helen M.; Guino, M.; Kiakos, K.; Hartley, J.A.; Searcey, M.; Patterson, Laurence H. | |||||||||
| Anti-colorectal cancer activity of an organometallic osmium arene azopyridine complex | 2011 | MedChemComm | 2 | 666 - 668 | Shnyder S.;Fu Y.;Habtemariam A.;Van Rijt S.;Cooper P.;Loadman P.;Sadler P. | 2040-2503 | 10.1039/c1md00075f | ||||
| Use of the hollow fiber assay for the evaluation of DNA damaging agents | 2011 | Journal of Pharmacological and Toxicological Methods | 64 | 226 - 232 | Veiga J.;Cooper P.;Pors K.;Patterson L.;Bibby M.;Shnyder S. | 1056-8719 | 10.1016/j.vascn.2011.04.006 | ||||
| Organometallic osmium arene complexes with potent cancer cell cytotoxicity | 2010 | Journal of Medicinal Chemistry | 53 | 8192 - 8196 | Fu Y.;Habtemariam A.;Pizarro A.;Van Rijt S.;Healey D.;Cooper P.;Shnyder S.;Clarkson G.;Sadler P. | 0022-2623 | 10.1021/jm100560f | ||||
| Improved preparation and detection of cytochrome P450 isoforms using MS methods | 2010 | Proteomics | 10 | 327 - 331 | Sutton C.;Sutherland M.;Shnyder S.;Patterson L. | 1615-9853 | 10.1002/pmic.200900489 | ||||
| Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases | 2010 | Cancer Research | 70 | 6902 - 6912 | Atkinson J.;Falconer R.;Edwards D.;Pennington C.;Siller C.;Shnyder S.;Bibby M.;Patterson L.;Loadman P.;Gill J. | 0008-5472 | 10.1158/0008-5472.CAN-10-1440 | ||||
| Development of a novel tumor-targeted vascular disrupting agent activated by Membrane-type Matrix Metalloproteinases (MT-MMPs) | 2010 | Atkinson, Jennifer M.; Falconer, Robert A.; Edwards, D.R.; Pennington, C.J.; Siller, Catherine S.; Shnyder, Steven D.; Bibby, Michael C.; Patterson, Laurence H.; Loadman, Paul M.; Gill, Jason H. | |||||||||
| Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor | 2010 | Gene Therapy | 17 | 1000 - 1010 | Harvey T.;Burdon D.;Steele L.;Ingram N.;Hall G.;Selby P.;Vile R.;Cooper P.;Shnyder S.;Chester J. | 0969-7128 | 10.1038/gt.2010.45 | ||||
| In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenograft. | 2009 | Williams, K.J.; Albertella, M.R.; Fitzpatrick, B.; Loadman, Paul M.; Shnyder, Steven D.; Chinje, E.C.; Telfer, B.A.; Dunk, C.R.; Harris, P.A.; Stratford, I.J. | |||||||||
| Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer | 2009 | Tomlinson, D.C.; Lamont, F.R.; Shnyder, Steven D.; Knowles, M.A. | |||||||||
| In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts | 2009 | Molecular Cancer Therapeutics | 8 | 3266 - 3275 | Williams K.;Albertella M.;Fitzpatrick B.;Loadman P.;Shnyder S.;Chinje E.;Telfer B.;Dunk C.;Harris P.;Stratford I. | 1535-7163 | 10.1158/1535-7163.MCT-09-0396 | ||||
| Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature. | 2009 | Shnyder, Steven D.; Jubb, E.; Hasan, J.; Cooper, Patricia A.; Bibby, Michael C.; Jayson, G.C.; Pilarinou, E. | |||||||||
| A cytotoxic diterpenoid from Croton membranaceus, the major constituent of anticancer herbal formulations used in Ghana | 2008 | Natural product communications | Bayor, M.T.;Ayim, J.S.K.;Marston, G.;Phillips, R.M.;Shnyder, S.D.;Wheelhouse, R.T.;Wright, C.W.; | ||||||||
| Guaianolide sesquiterpenes from Pulicaria crispa (Forssk.) Oliv. | 2008 | Phytochemistry | 69 | 1915 - 1918 | Stavri, M.; Matthew, K.T.; Gordon, Andrew; Shnyder, Steven D.; Falconer, Robert A.; Gibbons, S. | ||||||
| Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity | 2008 | Journal of Immunology | 180 | 8176 - 8183 | Krippner-Heidenreich A.;Grunwald I.;Zimmermann G.;Kühnle M.;Gerspach J.;Sterns T.;Shnyder S.;Gill J.;Männel D.;Pfizenmaier K.;Scheurich P. | 0022-1767 | 10.4049/jimmunol.180.12.8176 | ||||
| Triplex profiling of functionally distinct chaperones (ERp29/PDI/BiP) reveals marked heterogeneity of the endoplasmic reticulum proteome in cancer | 2008 | Journal of Proteome Research | 7 | 3364 - 3372 | Shnyder S.;Mangum J.;Hubbard M. | 1535-3893 | 10.1021/pr800126n | ||||
| A cytotoxic diterpenoid from Croton membranaceus, the major constituent of anticancer herbal formulations in Ghana | 2008 | Bayor, M.T.; Ayim, J.S.K.; Marston, G.; Phillips, Roger M.; Shnyder, Steven D.; Wheelhouse, Richard T.; Wright, Colin W. | |||||||||
| Sodium pancratistatin 3,4-O-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in a human colon tumor model | 2008 | Journal of Natural Products | 71 | 321 - 324 | Shnyder S.;Cooper P.;Millington N.;Gill J.;Bibby M. | 0163-3864 | 10.1021/np070477p | ||||
| Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models. | 2007 | Shnyder, Steven D.; Cooper, Patricia A.; Millington, Nicola J.; Pettit, G.R.; Bibby, Michael C. | |||||||||
| Synthesis of cryptolepine analogues as potential bioreducible anticancer agents | 2007 | Bioorganic and Medicinal Chemistry | 15 | 6353 - 6360 | Seville S.;Phillips R.;Shnyder S.;Wright C. | 0968-0896 | 10.1016/j.bmc.2007.06.062 | ||||
| Synthesis of DNA-Directed Pyrrolidinyl and Piperidinyl Confined Alkylating Chloroalkylaminoanthraquinones: Potential for Development of Tumor-Selective N-Oxides | 2006 | Patterson, Laurence H.; Pors, Klaus; Shnyder, Steven D.; Teesdale-Spittle, P.H.; Hartley, J.A.; Searcey, M.; Zloh, M. | |||||||||
| The hollow fibre model - Facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare | 2006 | International Journal of Oncology | 29 | 1493 - 1499 | Suggitt M.;Cooper P.;Shnyder S.;Bibby M. | 1019-6439 | |||||
| Reducing the cost of screening novel agents using the hollow fibre assay | 2006 | Anticancer Research | 26 | 2049 - 2052 | Shnyder S.;Cooper P.;Scally A.;Bibby M. | 0250-7005 | |||||
| Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates | 2006 | Journal of Medicinal Chemistry | 49 | 5442 - 5461 | Wells G.;Martin C.;Howard P.;Sands Z.;Laughton C.;Tiberghien A.;Woo C.;Masterson L.;Stephenson M.;Hartley J.;Jenkins T.;Shnyder S.;Loadman P.;Waring M.;Thurston D. | 0022-2623 | 10.1021/jm051199z | ||||
| Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action. | 2005 | Wright, Colin W.; Onyeibor, O.; Phillips, Roger M.; Shnyder, Steven D.; Croft, S.L.; Dodson, Hilary I. | |||||||||
| Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature | 2005 | Anticancer Research | 25 | 1889 - 1894 | Shnyder S.;Hasan J.;Cooper P.;Pilarinou E.;Jubb E.;Jayson G.;Bibby M. | 0250-7005 | |||||
| Heparin octasaccharides inhibit angiogenesis in vivo. | 2005 | Hasan, J.; Shnyder, Steven D.; Clamp, A.R.; McGown, A.T.; Bicknell, R.; Presta, M.; Bibby, Michael C.; Double, John A.; Craig, S.; Leeming, D.; Stevenson, K.; Gallagher, J.T.; Jayson, G.C. | |||||||||
| Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent. | 2004 | Wilkinson, Gary P.; Taylor, James P.; Shnyder, Steven D.; Loadman, Paul M.; Cooper, Patricia A.; Howard, P.W.; Thurston, D.E.; Jenkins, Terence C. | |||||||||
| Pharmacological and biological evaluation of a series of substituted 1,4 naphthoquinone bioreductive drugs. | 2004 | Phillips, Roger M.; Loadman, Paul M.; Maitland, Derek J.; Shnyder, Steven D.; Jaffar, M.; Steans, Gillian; Cooper, Patricia A.; Race, Amanda D.; Patterson, A.V.; Stratford, I.J. | |||||||||
| Secretory phospholipase A |
2004 | Molecular Cancer Therapeutics | 3 | 1451 - 1458 | Jensen S.;Andresen T.;Davidsen J.;Høyrup P.;Shnyder S.;Bibby M.;Gill J.;Jørgensen K. | 1535-7163 | |||||
| Comparative Preclinical Pharmacokinetic and Metabolic Studies of the Combretastatin Prodrugs Combretastatin A4 Phosphate and A1 Phosphate | 2004 | Kirwan, Ian G.; Loadman, Paul M.; Swaine, David J.; Anthoney, Alan; Pettit, G.R.; Lippert III, J.W.; Shnyder, Steven D.; Cooper, Patricia A.; Bibby, Michael C. | |||||||||
| Vinflunine Pierre Fabre/Bristol-Myers Squibb | 2004 | IDrugs : the investigational drugs journal | 7 | 851 - 859 | Shnyder S. | 1369-7056 | |||||
| Secretory phospholipase A2 as a tumor specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids | 2004 | Gill, Jason H.; Bibby, Michael C.; Jensen, S.S.; Shnyder, Steven D. | |||||||||
| Vinflunine Potentiates the Activity of Cisplatin but Not 5-Fluorouracil in A Transplantable Murine Adenocarcinoma Model | 2003 | Anticancer Research | 23 | 4815 - 4820 | Shnyder S.;Cooper P.;Gyselinck N.;Hill B.;Double J.;Bibby M. | 0250-7005 | |||||
| Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model | 2003 | Anticancer Research | 23 | 1619 - 1623 | Shnyder S.;Cooper P.;Pettit G.;Lippert J.;Bibby M. | 0250-7005 | |||||
| Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours | 2002 | Anticancer Research | 22 | 707 - 711 | Holwell S.;Cooper P.;Grosios K.;Lippert J.;Pettit G.;Shnyder S.;Bibby M. | 0250-7005 | |||||
| In vitro and in vivo activity of LS 4477 and LS 4559, novel analogues of the tubulin binder estramustine | 2002 | European Journal of Cancer. Part A | 38 | 194 - 204 | Nicholson K.;Phillips R.;Shnyder S.;Bibby M. | 0959-8049 | 10.1016/S0959-8049(01)00341-0 | ||||
| Use of the hollow fibre assay for studies of tumor neovasculature. | 2009 | Methods in molecular biology (Clifton, N.J.) | 467 | 331 - 342 | Shnyder S. | 1064-3745 | 10.1007/978-1-59745-241-0_21 | ||||
| Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer | 2019 | O'Flaherty, L.; Shnyder, Steven D.; Cooper, Patricia A.; Cross, S.J.; Wakefield, J.G.; Pardo, O.E.; Seckl, M.J.; Tavare, J.M. |
Reviews
| Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RGD-binding integrins in head and neck cancers | 2017 | Cancers | 9 | Ahmedah H.;Patterson L.;Shnyder S.;Sheldrake H. | 2072-6694 | 10.3390/cancers9060056 | |||||
| Non-invasive molecular imaging for preclinical cancer therapeutic development | 2013 | British Journal of Pharmacology | 169 | 719 - 735 | O'Farrell A.;Shnyder S.;Marston G.;Coletta P.;Gill J. | 0007-1188 | 10.1111/bph.12155 | ||||
| RGD-binding integrins in prostate cancer: Expression patterns and therapeutic prospects against bone metastasis | 2012 | Cancers | 4 | 1106 - 1145 | Sutherland M.;Gordon A.;Shnyder S.;Patterson L.;Sheldrake H. | 2072-6694 | 10.3390/cancers4041106 | ||||
| Quantitative angiogenesis assays in vivo - A review | 2004 | Angiogenesis | 7 | 1 - 16 | Hasan J.;Shnyder S.;Bibby M.;Double J.;Bicknel R.;Jayson G. | 0969-6970 | 10.1023/B:AGEN.0000037338.51851.d1 |